Optimizing first-line tki treatment efficacy in pd-l1-positive egfr-mutated nsclc: the impact of antiangiogenic agents

HIGHLIGHTS

• What: The analysis showed slightly worse but not statistically significant second-line PFS for PD-L1 (+) patients (9.3 vs. 14.7 months, P=0.15) . The study attempts to contribute to this area of research by exploring the potential efficacy of first-line TKI in combination therapy. The authors focused on the efficacy of combining first-line TKIs with antiangiogenic therapy, particularly in the context of PD-L1 expression. Given that patients with EGFR mutations often exhibit very low PD-L1 expression (Schoenfeld et_al, 2020), the study has chosen the 1% criterion.
• Who: NSCLC . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.